Oral isotretinoin fear in the treatment of acne vulgaris – assessment of dermatologist’s role in modification of patients’ concerns
DOI:
https://doi.org/10.20883/jofa.41Keywords:
acne vulgaris, oral isotretinoin, adverse effects of isotretinoinAbstract
Introduction. Acne vulgaris is a common, chronic, inflammatory disease which significantly affect the quality of life. Oral isotretinoin is an extremely effective drug used in the treatment of acne, nevertheless, it’s adverse effects raise concerns among patients.
Aim. The aim of the study was to determine dermatologist’s role in decreasing patients’ concerns about oral isotretinoin therapy in the treatment of acne vulgaris.
Material and Methods. 521 people who discussed oral isotretinoin therapy during a medical appointment filled an anonymous, online questionnaire. The respondents answered the questions about dermatologist’s impact on decreasing oral isotretinoin therapy fear.
Results. The respondents assessed dermatologist’s role in decreasing patients’ concerns about oral isotretinoin therapy on average to 7,07 ± 2,58 and the amount of time spent on discussing such a therapy to 6,78 ± 2,83 on average. There is a significant positive correlation between the amount of time spent on discussing oral isotretinoin therapy and the assessment of the dermatologist’s role in decreasing concerns about this treatment (R Spearman = +0,538; p < 0,05). 51,43% of the respondents declared reduction of their concerns after a doctor’s appointment. Better assessment of the amount of time spent on discussing oral isotretinoin therapy is positively correlated with reduction of the fear of such a treatment (R Spearman = +0,593; p < 0,05).
Conclusions. The results of our study indicate to dermatologist’s crucial role in disseminating reliable knowledge and education among patients about acne treatment. It is essential to devote an appropriate amount of time and due attention to the educational aspect of the treatment.
Downloads
References
Burgdorf WHC, Plewig G, Wolff HH, Landthaler M. Dermatologia Braun-Falco. Wydawnictwo CZELEJ, Lublin, 2010.
Oge' LK, Broussard A, Marshall MD. Acne Vulgaris: Diagnosis and Treatment. Am Fam Physician. 2019;100(8):475–484.
Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474–85.
Brzezinski P, Borowska K, Chiriac A, Smigielski J. Adverse effects of isotretinoin: A large, retrospective review. Dermatol Ther. 2017;30(4).
Bagatin E, Costa CS. The use of isotretinoin for acne – an update on optimal dosing, surveillance, and adverse effects. Expert Rev Clin Pharmacol. 2020;13(8):885–897.
Nast A, Dréno B, Bettoli V, Bukvic Mokos Z, Degitz K, Dressler C, Finlay AY, Haedersdal M, Lambert J, Layton A, Lomholt HB, López-Estebaranz JL, Ochsendorf F, Oprica C, Rosumeck S, Simonart T, Werner RN, Gollnick H. European evidence-based (S3) guideline for the treatment of acne – update 2016 – short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261–8.
Lowenstein EB, Lowenstein EJ. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero. Clin Dermatol. 2011;29(6):652–61.
Habeshian KA, Cohen BA. Current Issues in the Treatment of Acne Vulgaris. Pediatrics. 2020;145(Suppl 2):S225–S230.
Landis MN. Optimizing Isotretinoin Treatment of Acne: Update on Current Recommendations for Monitoring, Dosing, Safety, Adverse Effects, Compliance, and Outcomes. Am J Clin Dermatol. 2020;21(3):411–419.
Kaszuba A, Kaszuba A. Izotretinoina w leczeniu acne vulgaris, czyli co każdy dermatolog wiedzieć powinien. Wydawnictwo CZELEJ, Lublin, 2010.
Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, Patten SB. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76–85.
Melnik BC. Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity. Acta Derm Venereol. 2017;97(2):173–181.
Rademaker M. Adverse effects of isotretinoin: A retrospective review of 1743 patients started on isotretinoin. Australas J Dermatol. 2010;51(4):248–53.
Wolverton SE, Harper JC. Important controversies associated with isotretinoin therapy for acne. Am J Clin Dermatol. 2013;14(2):71–6.
Tugrul Ayanoglu B, Demirdag HG, Yalici Armagan B, Bezirgan O. Perceptions about oral isotretinoin treatment. Dermatol Ther. 2019;32(3):e12873.
Nagler AR, Orlow SJ. Dermatologists' attitudes, prescription, and counseling patterns for isotretinoin: a questionnaire-based study. J Drugs Dermatol. 2015;14(2):184–9.
Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, Patten SB. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018;178(1):76–85.
